TII
13.5.2024 15:37:31 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today launched a second iteration of its renowned large language model (LLM) – Falcon 2. Within this series, it has unveiled two groundbreaking versions: Falcon 2 11B, a more efficient and accessible LLM trained on 5.5 trillion tokens with 11 billion parameters, and Falcon 2 11B VLM, distinguished by its vision-to-language model (VLM) capabilities, which enable seamless conversion of visual inputs into textual outputs. While both models are multilingual, notably, Falcon 2 11B VLM stands out as TII's first multimodal model – and the only one currently in the top tier market that has this image-to-text conversion capability, marking a significant advancement in AI innovation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513516248/en/
Falcon Image Caption Generator (Photo: AETOSWire)
Tested against several prominent AI models in its class among pre-trained models, Falcon 2 11B surpasses the performance of Meta’s newly launched Llama 3 with 8 billion parameters (8B), and performs on par with Google’s Gemma 7B at first place (Falcon 2 11B: 64.28 vs Gemma 7B: 64.29), as independently verified by Hugging Face, a US-based platform hosting an objective evaluation tool and global leaderboard for open LLMs. More importantly, Falcon 2 11B and 11B VLM are both open-source, empowering developers worldwide with unrestricted access. In the near future, there are plans to broaden the Falcon 2 next-generation models, introducing a range of sizes. These models will be further enhanced with advanced machine learning capabilities like 'Mixture of Experts' (MoE), aimed at pushing their performance to even more sophisticated levels.
All of TII’s AI models released to date have consistently ranked in the top tier globally, as the most powerful open-source LLMs. The new scaled-down and versatile Falcon 2 11B models are set to give TII greater market adoption in the ever-evolving world of generative AI.
Falcon 2 11B models, equipped with multilingual capabilities, seamlessly tackle tasks in English, French, Spanish, German, Portuguese, and various other languages, enriching their versatility and magnifying their effectiveness across diverse scenarios. Falcon 2 11B VLM, a vision-to-language model, has the capability to identify and interpret images and visuals from the environment, providing a wide range of applications across industries such as healthcare, finance, e-commerce, education, and legal sectors. These applications range from document management, digital archiving, and context indexing to supporting individuals with visual impairments. Furthermore, these models can run efficiently on just one graphics processing unit (GPU), making them highly scalable, and easy to deploy and integrate into lighter infrastructures like laptops and other devices.
H.E. Faisal Al Bannai, Secretary General of ATRC and Strategic Research and Advanced Technology Affairs Advisor to the UAE President, said: "With the release of Falcon 2 11B, we've introduced the first model in the Falcon 2 series. While Falcon 2 11B has demonstrated outstanding performance, we reaffirm our commitment to the open-source movement with it, and to the Falcon Foundation. With other multimodal models soon coming to the market in various sizes, our aim is to ensure that developers and entities that value their privacy have access to one of the best AI models to enable their AI journey."
Speaking on the model, Dr. Hakim Hacid, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: “AI is continually evolving, and developers are recognizing the myriad benefits of smaller, more efficient models. In addition to reducing computing power requirements and meeting sustainability criteria, these models offer enhanced flexibility, seamlessly integrating into edge AI infrastructure, the next emerging megatrend. Furthermore, the vision-to-language capabilities of Falcon 2 open new horizons for accessibility in AI, empowering users with transformative image to text interactions.”
The versatility of Falcon 2 11B has also led TII to consider working on more exciting GenAI innovations. Among these will be the adoption of a new type of machine learning capability known as the aforementioned ‘Mixture of Experts’. This method involves amalgamating smaller networks with distinct specializations, ensuring that the most knowledgeable domains collaborate to deliver highly sophisticated and customized responses – almost like having a team of smart helpers who each know something different and work together to predict or make decisions when needed. This approach not only improves accuracy, but it also accelerates decision-making, paving the way for more intelligent and efficient AI systems.
Falcon 2 11B is licenced under TII Falcon License 2.0, the permissive Apache 2.0-based software license which includes an acceptable use policy that promotes the responsible use of AI. More information on the new model can be found at FalconLLM.TII.ae.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513516248/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
